Department of Pathology, University of Washington, Seattle, Washington 98195, USA.
J Am Soc Nephrol. 2013 Jun;24(7):1088-102. doi: 10.1681/ASN.2012050445. Epub 2013 May 2.
The reversibility of diabetic nephropathy remains controversial. Here, we tested whether replacing leptin could reverse the advanced diabetic nephropathy modeled by the leptin-deficient BTBR ob/ob mouse. Leptin replacement, but not inhibition of the renin-angiotensin-aldosterone system (RAAS), resulted in near-complete reversal of both structural (mesangial matrix expansion, mesangiolysis, basement membrane thickening, podocyte loss) and functional (proteinuria, accumulation of reactive oxygen species) measures of advanced diabetic nephropathy. Immunohistochemical labeling with the podocyte markers Wilms tumor 1 and p57 identified parietal epithelial cells as a possible source of regenerating podocytes. Thus, the leptin-deficient BTBR ob/ob mouse provides a model of advanced but reversible diabetic nephropathy for further study. These results also suggest that restoration of lost podocytes is possible but is not induced by RAAS inhibition, possibly explaining the limited efficacy of RAAS inhibitors in promoting repair of diabetic nephropathy.
糖尿病肾病的可逆性仍存在争议。在这里,我们测试了补充瘦素是否可以逆转由瘦素缺乏的 BTBR ob/ob 小鼠所建立的晚期糖尿病肾病模型。瘦素替代治疗,而不是肾素-血管紧张素-醛固酮系统(RAAS)的抑制,导致晚期糖尿病肾病的结构(肾小球系膜基质扩张、肾小球溶解、基底膜增厚、足细胞丢失)和功能(蛋白尿、活性氧物质积累)指标几乎完全逆转。用足细胞标志物 Wilms 肿瘤 1 和 p57 进行免疫组织化学标记,将壁细胞确定为再生足细胞的可能来源。因此,瘦素缺乏的 BTBR ob/ob 小鼠为进一步研究提供了一种晚期但可逆转的糖尿病肾病模型。这些结果还表明,丢失的足细胞的恢复是可能的,但不受 RAAS 抑制的诱导,这可能解释了 RAAS 抑制剂在促进糖尿病肾病修复方面的疗效有限。